Current Topics in Behavioral Neurosciences
2026
Tomislav Majić, Euphrosyne Gouzoulis‐mayfrank, Ricarda Evens
2 citations
Classic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and 5-methoxy-dimethyltryptamine (5-MeO-DMT) have shown promising effects in the treatment of certain mental health conditions. Enthusiastic claims about their therapeutic potential have led to overly optimistic reactions in the media and the public, subsequently resulting in increased use outside of clinical contexts...
Addiction
July 26, 2012
Daniel Wagner, Benjamin Becker, Philip Koester et al.
54 citations
Abstract Aims It is still unclear if cognitive abnormalities in human 3,4‐methylenedioxymeth‐amphetamine ( MDMA ) users existed before the beginning of use or if other confounders could explain the deficits. The present study was conducted in order to assess the relationship between beginning MDMA use and subsequent cognitive performance and to overcome previous methodological shortcomings....
Dialogues in Clinical Neuroscience
September 30, 2009
Euphrosyne Gouzoulis‐mayfrank, Jörg Daumann
115 citations
Ecstasy (MDMA, 3,4-methylendioxymethamphetamine) and the stimulants methamphetamine (METH, speed) and amphetamine are popular drugs among young people, particularly in the dance scene. When given in high doses both MDMA and the stimulant amphetamines are clearly neurotoxic in laboratory animals. MDMA causes selective and persistent lesions of central serotonergic nerve terminals, whereas...
Journal of Psychopharmacology
March 20, 2009
Jörg Daumann, Daniel Wagner, Karsten Heekeren et al.
62 citations
Deficits in attentional functions belong to the core cognitive symptoms in schizophrenic patients. Alertness is a nonselective attention component that refers to a state of general readiness that improves stimulus processing and response initiation. The main goal of the present study was to investigate cerebral correlates of alertness in the human 5HT(2A) agonist and N-methyl-D-aspartic acid...
Psychopharmacology
November 2008
Jörg Daumann, Karsten Heekeren, Anna Neukirch et al.
Attentional deficits are common symptoms in schizophrenia. Recent evidence suggests that schizophrenic patients show abnormalities in spatial orienting of attention, particularly a deficit of inhibition of return (IOR). IOR is mostly thought to reflect an automatic, inhibitory mechanism protecting the organism from redirecting attention to previously scanned, insignificant locations....
Psychopharmacology
May 16, 2008
Karsten Heekeren, Jörg Daumann, Anna Neukirch et al.
158 citations
RATIONALE: Many studies have reported deficits of mismatch negativity (MMN) in schizophrenic patients. Pharmacological challenges with hallucinogens in healthy humans are used as models for psychotic states. Previous studies reported a significant reduction of MMN after ketamine (N-methyl-D-aspartate acid [NMDA] antagonist model) but not after psilocybin (5HT2A agonist model). OBJECTIVES: The...
Journal of Psychopharmacology
May 1, 2007
Karsten Heekeren, Anna Neukirch, Jörg Daumann et al.
49 citations
Patients with schizophrenia exhibit diminished prepuLse inhibition (PPI) of the acoustic startle reflex and deficits in the attentional moduLation of PPI. Pharmacological challenges with hallucinogens are used as models for psychosis in both humans and animals. RemarkabLy, in contrast to the findings in schizophrenic patients and in animal hallucinogen modeLs of psychosis, previous studies with...
Journal of Psychopharmacology
March 1, 2006
Euphrosyne Gouzoulis‐mayfrank, Jörg Daumann
179 citations
The popular dance drug ecstasy (3,4-methylenedioxymethamphetamine -- MDMA) is neurotoxic upon central serotonergic neurons in laboratory animals and possibly also in humans. In recent years, several studies reported alterations of serotonergic transmission and neuropsychiatric abnormalities in ecstasy users which might be related to MDMA-induced neurotoxic brain damage. To date, the most...
Journal of psychopharmacology (Oxford, England)
March 2006
Jörg Daumann, Bianca Till, Thomas Fischermann et al.
Numerous animal studies have been able to demonstrate neurotoxic damage to central serotonergic systems after exposure to 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). It has been suggested that a high loudness dependence of auditory evoked potentials (LDAEP) and, particularly, of the tangential N1/P2 source activity is associated with a low functioning of serotonergic activity. Therefore,...
Addiction
February 27, 2006
Euphrosyne Gouzoulis‐mayfrank, Jörg Daumann
189 citations
ABSTRACT Background The popular dance drug ecstasy (3,4‐methylenedioxymethamphetamine: MDMA and some analogues) causes selective and persistent neurotoxic damage of central serotonergic neurones in laboratory animals. Serotonin plays a role in numerous functional systems in the central nervous system (CNS). Consequently, various abnormalities including psychiatric, vegetative, neuroendocrine...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
February 2006
Euphrosyne Gouzoulis‐mayfrank, Karsten Heekeren, Anna Neukirch et al.
Patients with schizophrenia exhibit disturbances of orienting of attention. However, findings have been inconsistent. Pharmacologic challenges with hallucinogens have been used as models for psychosis. The NMDA antagonist state (PCP, ketamine) resembles undifferentiated psychoses with positive and negative symptoms, while the 5-HT(2A) agonist state (LSD, dimethyltryptamine (DMT)) is thought to...
Pharmacopsychiatry
November 1, 2005
Euphrosyne Gouzoulis‐mayfrank, Karsten Heekeren, Anna Neukirch et al.
198 citations
INTRODUCTION: Pharmacological challenges with hallucinogens are used as models for psychosis in experimental research. The state induced by glutamate antagonists such as phencyclidine (PCP) is often considered as a more appropriate model of psychosis than the state induced by serotonergic hallucinogens such as lysergic acid diethylamide (LSD), psilocybin and N,N-dimethyltryptamine (DMT)....
Pharmacopsychiatry
September 1, 2005
Euphrosyne Gouzoulis‐mayfrank, Anna Neukirch, Karsten Heekeren
2 citations
Pharmacological challenges with hallucinogens are used as models for psychosis in experimental research. The state induced by glutamate antagonists such as phencyclidine (PCP) is often considered as a more appropriate model of psychosis than the state induced by serotonergic hallucinogens such as lysergic acid (LSD), psilocybin and dimethyltryptamine (DMT). However, so far, this question has...
Psychopharmacology
May 2004
Karsten Heekeren, Jörg Daumann, Mark A Geyer et al.
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is neurotoxic upon central serotonin systems in experimental animals and probably also in humans. Serotonin is involved in the habituation, sensitization and prepulse inhibition (PPI) of the startle reflex. To study the plasticity of startle reflex in currently abstinent MDMA users. Electromyographic responses to acoustic startle stimuli (pulse...
Neuroreport
October 1, 2003
Jörg Daumann, Ralph Schnitker, Jürgen Weidemann et al.
46 citations
Poor cognitive performance in ecstasy (3,4-methylenedioxymethamphetamine; MDMA) users has been related to the well-recognized neurotoxic effects of the drug upon central serotonergic and possibly also dopaminergic systems. However, concomitant use of other drugs has been a critical confound in most investigations. In this study we used an n-back task and fMRI to investigate working memory...
Neuropsychobiology
2002
Euphrosyne Gouzoulis‐mayfrank, B. Thelen, Stefanie Maier et al.
69 citations
Hallucinogenic drug-induced states are considered as models for acute schizophrenic disorders (experimental psychoses). In a double-blind study with healthy volunteers we investigated the influence of the serotonergic hallucinogen psilocybin, the ecstasy-like drug 3,4-methylenedioxyethylamphetamine (MDE), the stimulant d- methamphetamine and placebo on covert orienting of spatial attention (n =...
Human Psychopharmacology Clinical and Experimental
December 1, 2001
Jörg Daumann, Susanna Pelz, Stefanie Becker et al.
77 citations
Abstract The popular recreational drug Ecstasy (3,4‐methylenedioxymethamphetamine, or MDMA, and related congeners) is neurotoxic upon central serotonergic systems in animal studies. So far, the most convincing evidence for neurotoxicity‐related functional deficits in humans derives from neurocognitive studies demonstrating dose‐related memory problems in Ecstasy users. The aim of the current...
Journal of Neurology Neurosurgery & Psychiatry
June 1, 2000
Euphrosyne Gouzoulis‐mayfrank
309 citations
The present data raise concern that use of ecstasy possibly in conjunction with cannabis may lead to cognitive decline in otherwise healthy young people. Although the nature of the emerging cognitive disturbance is not yet clear, an impairment of working memory might be the common denominator underlying or contributing to declines of performance in various tasks. The cognitive disturbance is...
Neuropsychopharmacology
June 1, 1999
Euphrosyne Gouzoulis‐mayfrank
224 citations
The neurometabolic effects of the hallucinogen psilocybin (PSI; 0.2 mg/kg), the entactogen 3,4-methylenedioxyethylamphetamine (MDE; 2 mg/kg) and the stimulant d-methamphetamine (METH; 0.2-0.4 mg/kg) and the drugs' interactions with a prefrontal activation task were investigated in a double-blind, placebo-controlled human [F-18]fluorodeoxyglucoseFDG-positron emission tomographicPET study (each...
Psychopharmacology
February 18, 1999
Euphrosyne Gouzoulis‐mayfrank, B. Thelen, Elmar Habermeyer et al.
145 citations
The aim of this study was to contribute to the characterization of the entactogen (ecstasy) substance group. The psychopathological, neuroendocrine and autonomic effects of common recreational doses of the entactogen 3,4-methylenedioxyethylamphetamine (MDE), the hallucinogen psilocybin, the stimulant d-methamphetamine and placebo were investigated in a double-blind study with healthy volunteers...
European psychiatry : the journal of the Association of European Psychiatrists
December 1, 1998
Euphrosyne Gouzoulis‐mayfrank, Elmar Habermeyer, L Hermle et al.
Clinical evidence suggests that hallucinogenic drug-induced altered states of consciousness (ASCs) and the incipient, acute stages of endogenous psychoses share many common phenomenological features. The aim of our study was to assess hallucinogen-like phenomena in endogenous psychotic patients using standardised methods. We examined 93 endogenous psychotic patients, 50 healthy controls and a...
Behavioural Pharmacology
November 1, 1998
Euphrosyne Gouzoulis‐mayfrank, Karsten Heekeren, B. Thelen et al.
79 citations
Schizophrenic patients exhibit deficits in indices of sensorimotor gating, such as habituation and prepulse inhibition (PPI) of the startle reflex. Hallucinogenic drug-induced states are putative models for the early and acute stages of schizophrenic and schizophrenia-spectrum disorders. Hallucinogenic drugs have been shown to disrupt PPI and/or retard habituation of the startle reflex in...
Pharmacopsychiatry
July 1, 1998
Leo Hermle, Euphrosyne Gouzoulis‐mayfrank, Matthew W. Spitzer
44 citations
The psychological, neuropsychological, and neurometabolic effects of the hallucinogenic agent mescaline were investigated in 12 normal male volunteers. Between 3 1/2 and 4 hours after drug intake, mescaline produced an acute psychotomimetic state, as measured by the BPRS and PDS-P. The APZ questionnaire revealed the specific effects of mescaline in the visual system. Neuropsychological effects...
Pharmacopsychiatry
July 1, 1998
Euphrosyne Gouzoulis‐mayfrank, Frank Schneider, J. Friedrich et al.
16 citations
Human experimental research with hallucinogenic drugs is potentially able to identify linking variables between the psycho(patho)logical conditions and neurobiological alterations involved in both pharmacologically induced and naturally occurring acute psychotic states. A number of methodological aspects should be considered when planning modern experimental studies with hallucinogenic drugs....
Pharmacopsychiatry
July 1998
Euphrosyne Gouzoulis‐mayfrank, L Hermle, B Thelen et al.
Systematic scientific interest in psychedelic substances has a tradition of about 100 years. Numerous human experimental studies have confirmed the existence of a common nucleus of experiences in hallucinogen-induced states and the acute stages of schizophrenic psychoses. However, the degree of resemblance between endogenous and drug-induced psychotic states has been an issue of controversial...